Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

PURPOSE: Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for advanced MCC (aMCC) demonstrate increased progression-free survival (PFS) compared with historical chemotherapy data. Howe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Nghiem, Paul, Bhatia, Shailender, Lipson, Evan J., Sharfman, William H., Kudchadkar, Ragini R., Brohl, Andrew S., Friedlander, Phillip A., Daud, Adil, Kluger, Harriet M., Reddy, Sunil A., Boulmay, Brian C., Riker, Adam I., Burgess, Melissa A., Hanks, Brent A., Olencki, Thomas, Margolin, Kim, Lundgren, Lisa M., Soni, Abha, Ramchurren, Nirasha, Church, Candice, Park, Song Y., Shinohara, Michi M., Salim, Bob, Taube, Janis M., Bird, Steven R., Ibrahim, Nageatte, Fling, Steven P., Homet Moreno, Blanca, Sharon, Elad, Cheever, Martin A., Topalian, Suzanne L.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2019
Materias:
Rapid Communication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6424137/
https://ncbi.nlm.nih.gov/pubmed/30726175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01896
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares